Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Alzheimer’s Therapeutics Market

Alzheimer’s Therapeutics Market Share

Report ID: GMI10124
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Alzheimer’s Therapeutics Market Share

The Alzheimer’s therapeutics industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The market is characterized by significant growth, driven by the increasing prevalence of Alzheimer’s disease, especially among the aging global population.

Market share is dominated by North America and Europe due to their advanced healthcare infrastructure, robust R&D capabilities, and strong regulatory frameworks. Major pharmaceutical companies such as Biogen, Eisai, and Eli Lilly lead in developing innovative treatments, including disease-modifying therapies and symptomatic treatments. Emerging markets in Asia-Pacific, particularly Japan and China, are also witnessing rapid growth due to rising awareness, improved healthcare facilities, and increased government support.

Alzheimer’s Therapeutics Market Companies

Prominent players operating in the Alzheimer’s therapeutics industry include:

AbbVie Inc.
Amgen Inc.
AstraZeneca
Biogen
Cipla Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
H. Lundbeck A/S
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer, Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Alzheimer’s therapeutics market was valued at USD 5.8 billion in 2023 and is expected to exhibit growth at 9.8% CAGR from 2024 – 2032 attributed to the ongoing advancements in diagnostic technologies.

The oral segment in the market accounted for 58% share in 2023 as taking a pill is less intrusive and more manageable for daily routines.

North America Alzheimer’s therapeutics market accounted for USD 2.2 billion in revenue in 2023 owing to the highly developed healthcare infrastructure, including state-of-the-art hospitals, and research facilities.

AbbVie Inc., Amgen Inc., AstraZeneca, Biogen, Cipla Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, H. Lundbeck A/S, and Merck & Co., Inc. among others.